TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics. The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility spanning an area of 59,000 square feet (approximately 5,481 square meters) in Berlin.

东京&纽约&德塞尔多夫——（商业新闻短讯）——旭化成生物工艺（AKB）是旭化成集团的一部分，Axolabs宣布在新兴的寡核苷酸治疗领域建立战略合作伙伴关系。合作伙伴将合作在柏林建立一个占地59000平方英尺（约5481平方米）的尖端寡核苷酸cGMP生产设施。

This cooperation aims to accelerate the development and commercialization of oligonucleotide-based therapies to improve quality of life for patients worldwide..

这种合作旨在加速基于寡核苷酸的疗法的开发和商业化，以提高全球患者的生活质量。。

Oligonucleotide therapies offer a targeted approach to modulating gene expression, splicing, and protein production. By selectively manipulating specific molecular processes, these therapies hold the potential to treat a wide range of diseases (e.g., genetic disorders, cancer, and certain viral infections) at the genetic level, providing new treatment options for patients.

寡核苷酸疗法提供了一种有针对性的方法来调节基因表达，剪接和蛋白质产生。通过选择性地操纵特定的分子过程，这些疗法具有在遗传水平上治疗多种疾病（例如遗传疾病，癌症和某些病毒感染）的潜力，为患者提供了新的治疗选择。

In recent years, remarkable advancements in nucleic acid chemistry and cell biology have contributed to refining the design and optimization of oligonucleotide therapies, as well as their delivery mechanisms. Currently, a total of 25 approved oligonucleotide therapeutics have been approved by regulatory authorities worldwide, and numerous others are in pre-clinical and clinical studies with promising prospects for further development..

近年来，核酸化学和细胞生物学的显着进步有助于改进寡核苷酸疗法的设计和优化及其递送机制。目前，全世界共有25种经批准的寡核苷酸治疗药物已获得监管机构的批准，还有许多其他药物正在进行临床前和临床研究，具有广阔的进一步发展前景。。

To meet the escalating demand for oligonucleotide therapeutics, Axolabs, a CRDMO providing drug substances for oligonucleotide-based therapeutics, is establishing a new GMP manufacturing hub in Berlin. By utilizing the unique expertise of AKB, specializing in the field of oligosynthesis equipment, and Axolabs, the facility will serve as a pivotal resource to expedite therapeutic breakthroughs in the industry.

为了满足日益增长的寡核苷酸治疗需求，Axolabs（一家为寡核苷酸治疗提供药物的CRDMO）正在柏林建立一个新的GMP制造中心。通过利用AKB（专注于寡聚合成设备领域）和Axolabs的独特专业知识，该设施将成为加速行业治疗突破的关键资源。

It is designed to accommodate a wide range of production scales (small to large/commercial) and will benefit from AKB’s robust suite of oligo manufacturing equipment—covering all upstream and downstream manufacturing unit operations from synthesis to concentration—all of which is purpose-built to maximize productivity and provide years of reliable operation..

它旨在适应广泛的生产规模（从小到大/商业），并将受益于AKB强大的寡核苷酸制造设备套件，涵盖从合成到浓缩的所有上游和下游制造单元操作，所有这些都是为了最大限度地提高生产力并提供多年可靠的运行。。

'We are thrilled to join forces with Axolabs in this transformative endeavor. Our combined technical expertise and strategic alignment will bolster our commitment to meet and exceed the growing needs of the oligonucleotide therapeutics field,' said Chris Rombach, SVP of Sales and Marketing at AKB. 'Moreover, our involvement from the very early stages of the project allows us to support and facilitate future scale-up efficiently.'.

“我们很高兴能与Axolabs携手进行这项变革性的努力。AKB销售和营销高级副总裁克里斯·罗姆巴赫（ChrisRombach）说，我们的综合技术专长和战略协调将加强我们满足和超越寡核苷酸治疗领域日益增长的需求的承诺此外，我们在项目早期阶段的参与使我们能够有效地支持和促进未来的规模扩大。”。

Thomas Rupp, Managing Director of Technology & Production at Axolabs, echoed the sentiment, 'Partnering with AKB provides a unique opportunity to blend our respective strengths. We are confident that this collaboration will foster innovation and drive the production of high-quality oligonucleotide therapeutics.'.

Axolabs技术与生产董事总经理托马斯·鲁普（ThomasRupp）回应了这一观点，“与AKB合作提供了一个独特的机会，可以融合我们各自的优势。我们相信，这种合作将促进创新，推动高质量寡核苷酸治疗剂的生产。”。

Operations at the newly built facility are planned to commence in late 2024.

新建设施的运营计划于2024年末开始。

About Asahi Kasei Bioprocess

关于旭化成生物工艺

The Fluid Management Business Unit of Asahi Kasei Bioprocess is devoted to solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for oligonucleotide synthesis, buffer formulation, chromatography, and filtration, our bioprocess systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world.

旭化成生物工艺的流体管理业务部门致力于解决制药和生物加工行业中治疗产品的安全性，效率和纯度挑战。凭借寡核苷酸合成、缓冲液配制、色谱和过滤的技术平台，我们的生物过程系统、色谱柱和自动化解决方案推动了全球关键药物的GMP生产。

Built with pride, built with quality, built to exceed expectations. “Built for You.” For more information, please visit https://fluidmgmt.ak-bio.com..

自豪而生，品质而生，超越期望而生。“专为您打造。”有关更多信息，请访问https://fluidmgmt.ak-bio.com..

About Axolabs

关于Axolabs

Axolabs specializes in a new class of drugs whose active ingredients are chemically derived from DNA or RNA, known as oligonucleotides or nucleic acid therapeutics. Using our many years of expertise we help our clients make their oligonucleotide-based therapeutic a success. With sites in Germany and United States, Axolabs counts the majority of research groups in the field of nucleic acid and oligonucleotide-based therapeutics worldwide among its clients, including >20 big pharma enterprises, >250 biotech companies, >30 academic research institutes and venture capital firms..

Axolabs专门研究一类新型药物，其活性成分化学来源于DNA或RNA，称为寡核苷酸或核酸疗法。利用我们多年的专业知识，我们帮助客户成功实现基于寡核苷酸的治疗。Axolabs在德国和美国设有分支机构，其客户包括全球核酸和寡核苷酸治疗领域的大多数研究小组，其中包括20多家大型制药企业、250多家生物技术公司、30多家学术研究机构和风险投资公司。。

Axolabs is part of LGC Group. For more information, please visit https://www.axolabs.com.

Axolabs是LGC集团的一部分。有关更多信息，请访问https://www.axolabs.com.

About Asahi Kasei

关于旭化成

The Asahi Kasei Group contributes to life and living for people around the world. Since its founding in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care.

旭化成集团为全世界人民的生活做出了贡献。自1922年成立氨纤维和纤维素纤维业务以来，旭化成一直通过积极的业务组合转型来满足各个年龄段不断变化的需求。该公司在全球拥有48000多名员工，通过其材料、住房和医疗保健三个业务部门为世界挑战提供解决方案，为可持续发展的社会做出了贡献。

Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com/..

其医疗保健业务包括用于急性重症监护、透析、治疗性单采血液分离、生物治疗药物制造以及药物和诊断试剂的设备和系统。有关更多信息，请访问www.asahi-kasei.com/。。

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon-neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.

旭化成还致力于可持续发展倡议，并为到2050年实现碳中和社会做出贡献。要了解更多信息，请访问https://www.asahi-kasei.com/sustainability/.